Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
IPO Year:
Exchange: NYSE
Website: teleflex.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/8/2026 | $155.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 4/13/2026 | $135.00 | Underperform → Neutral | BofA Securities |
| 3/27/2026 | $128.00 | Mkt Perform → Outperform | Raymond James |
| 1/27/2026 | $138.00 | Hold → Buy | Needham |
| 3/4/2025 | $235.00 → $140.00 | Neutral → Underperform | BofA Securities |
| 2/28/2025 | $220.00 → $155.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 2/28/2025 | Outperform → Mkt Perform | Raymond James | |
| 2/28/2025 | $255.00 → $140.00 | Overweight → Neutral | Piper Sandler |
| 2/27/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 7/1/2024 | $205.00 → $245.00 | Neutral → Overweight | Piper Sandler |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
8-K - TELEFLEX INC (0000096943) (Filer)
SD - TELEFLEX INC (0000096943) (Filer)
8-K - TELEFLEX INC (0000096943) (Filer)
8-K - TELEFLEX INC (0000096943) (Filer)
10-Q - TELEFLEX INC (0000096943) (Filer)
8-K - TELEFLEX INC (0000096943) (Filer)
8-K - TELEFLEX INC (0000096943) (Filer)
DEF 14A - TELEFLEX INC (0000096943) (Filer)
8-K - TELEFLEX INC (0000096943) (Filer)
SCHEDULE 13G/A - TELEFLEX INC (0000096943) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
RBC Capital Mkts upgraded Teleflex from Sector Perform to Outperform and set a new price target of $155.00
BofA Securities upgraded Teleflex from Underperform to Neutral and set a new price target of $135.00
Raymond James upgraded Teleflex from Mkt Perform to Outperform and set a new price target of $128.00
Needham upgraded Teleflex from Hold to Buy and set a new price target of $138.00
BofA Securities downgraded Teleflex from Neutral to Underperform and set a new price target of $140.00 from $235.00 previously
RBC Capital Mkts downgraded Teleflex from Outperform to Sector Perform and set a new price target of $155.00 from $220.00 previously
Raymond James downgraded Teleflex from Outperform to Mkt Perform
Piper Sandler downgraded Teleflex from Overweight to Neutral and set a new price target of $140.00 from $255.00 previously
Citizens JMP downgraded Teleflex from Mkt Outperform to Mkt Perform
Piper Sandler upgraded Teleflex from Neutral to Overweight and set a new price target of $245.00 from $205.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
3 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
3 - TELEFLEX INC (0000096943) (Issuer)
4 - TELEFLEX INC (0000096943) (Issuer)
Fastest customizable press release news feed in the world
Teleflex Incorporated (NYSE:TFX) ("Teleflex") announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due 2032 (the "Notes") at an issue price of 100.000%. The sale of the Notes is expected to close on June 15, 2026, subject to customary closing conditions. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness. Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the "2027 Notes").
Teleflex Incorporated (NYSE:TFX) ("Teleflex") announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032 (the "Notes"), subject to market and other conditions. The interest rate and other terms of the Notes will be determined at pricing. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness. Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the "2027 Notes"). The offering of t
First Head-to-Head Randomized Control Study (RCT) Reinforces Early Patient Experience Benefits and 12-month Durability of the UroLift™ System versus Rezūm™1 Three-Year Data Demonstrate Sustained Reduction in Gastrointestinal Toxicity with Barrigel™ Rectal Spacer2 Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innova
Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believ
Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 31, 2026. First quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period Adjusted diluted EPS from continuing operations of $1.39, compared to $1.44 in the prior year period 2026 continuing operations guidance summary1 Maintaining GAAP revenue growth guidance range of 14.40% to 15.40% Maintaining pro for
Proven Industry Leader to Guide Company's Next Chapter of Growth and Value Creation Teleflex Incorporated (NYSE:TFX) today announced that Jason Weidman has been appointed President and Chief Executive Officer, effective June 8, 2026. He will succeed Stuart Randle, who has been serving as Interim President and CEO since January 2026 and will continue as a member of Teleflex's Board of Directors. Mr. Weidman is expected to join the Teleflex Board when he assumes his role as President and CEO. Mr. Weidman is a proven medical technology leader with over 25 years of industry experience and a strong track record of building and scaling businesses globally. He joins Teleflex from Medtronic plc
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 7, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 a.m. Eastern Time on May 7, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.
Michael J. Tokich, Medical Technology Industry Veteran, Nominated as Independent Director; Andrew A. Krakauer Appointed Chairman of the Board Effective Following 2026 Annual Meeting Board to Establish Growth and Operating Committee Company to Commence Share Repurchases Ahead of Schedule Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced several Board and governance updates, including the nomination of Michael J. Tokich to the Board of Directors, its intent to establish a new Growth and Operating Committee of the Board and its plan to commence share repurchases under the Company's previously announced program ahead of schedule. The an
Calls on Board to Establish Strategic Review Sub-Committee with New Independent Directors to Oversee Process Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX) with 2% ownership, today issued the following statement regarding the Company's recent announcement: "We welcome Teleflex's newfound openness to consider all strategic alternatives. As a next step, we believe the Board of Directors should form a Strategic Review sub-committee with new independent directors, including a shareholder representative and excluding Dr. Klasko, to work with its advisors to both engage with inbound approaches and solicit outb
Previously Announced Sale Transactions on Track to Close in Second Half of 2026; Expecting $1.8 Billion of Net Proceeds for Buyback and Debt Paydown Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic Capital Management L.P. ("Irenic"). The Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders. Members of the Board and management team met with Irenic at their request on March 19, 2026, to better understand their views and underscore the Company's commitment to maximizing value for shareholders.
Live Leadership Updates
Proven Industry Leader to Guide Company's Next Chapter of Growth and Value Creation Teleflex Incorporated (NYSE:TFX) today announced that Jason Weidman has been appointed President and Chief Executive Officer, effective June 8, 2026. He will succeed Stuart Randle, who has been serving as Interim President and CEO since January 2026 and will continue as a member of Teleflex's Board of Directors. Mr. Weidman is expected to join the Teleflex Board when he assumes his role as President and CEO. Mr. Weidman is a proven medical technology leader with over 25 years of industry experience and a strong track record of building and scaling businesses globally. He joins Teleflex from Medtronic plc
Michael J. Tokich, Medical Technology Industry Veteran, Nominated as Independent Director; Andrew A. Krakauer Appointed Chairman of the Board Effective Following 2026 Annual Meeting Board to Establish Growth and Operating Committee Company to Commence Share Repurchases Ahead of Schedule Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced several Board and governance updates, including the nomination of Michael J. Tokich to the Board of Directors, its intent to establish a new Growth and Operating Committee of the Board and its plan to commence share repurchases under the Company's previously announced program ahead of schedule. The an
Previously Announced Sale Transactions on Track to Close in Second Half of 2026; Expecting $1.8 Billion of Net Proceeds for Buyback and Debt Paydown Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic Capital Management L.P. ("Irenic"). The Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders. Members of the Board and management team met with Irenic at their request on March 19, 2026, to better understand their views and underscore the Company's commitment to maximizing value for shareholders.
Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi
Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Revenue Results WAYNE, Pa., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that Stuart Randle, a member of the Company's Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately. Mr. Randle succeeds Liam Kelly, who departs as Chairman, President and CEO of the Company. Dr. Stephen Klasko, the Company's Lead Director, has been named Chairman of the Board. The Board has engaged Spencer Stuart, a leading execu
NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With
WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des
Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon
ROCK HILL, S.C., May 16, 2022 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE:DDD) announced the formation of the company's first Medical Advisory Board (MAB) and the appointment of Stephen K. Klasko, MD, MBA as Chair. The primary mission of the MAB will be to provide strategic input, guidance, and recommendations for the company's emerging regenerative medicine efforts as they begin moving from research into advanced development and, ultimately, into human application. The MAB will comprise a diverse spectrum of skill sets and experiences ranging from scientific expertise to commercial application, including advising on the formation of key partnerships to reduce program risks and accelerate
This live feed shows all institutional transactions in real time.
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
SC 13G - TELEFLEX INC (0000096943) (Subject)
SC 13G/A - TELEFLEX INC (0000096943) (Subject)
Live finance-specific insights
Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believ
Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 31, 2026. First quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period Adjusted diluted EPS from continuing operations of $1.39, compared to $1.44 in the prior year period 2026 continuing operations guidance summary1 Maintaining GAAP revenue growth guidance range of 14.40% to 15.40% Maintaining pro for
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 7, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 a.m. Eastern Time on May 7, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.
Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company's Sustained Value Destruction, Lack of Permanent Leadership, and Board's Poor Alignment with Shareholders Contends Meaningful Board Change – Including a New Chair – and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE:TFX) with 2% ownership, today sent the below letter to the Company's Board of Directors (the "Board") regarding its refusal to engage with potential acquirors, despite receiv
Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 31, 2026, to shareholders of record at the close of business on March 6, 2026. Additional information about Teleflex can be obtained from the company's website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency me
Announces Restructuring to Right-Size and Reduce Cost Structure Related to Announced Strategic Divestitures Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the year ended December 31, 2025. Full year 2025 continuing operations financial summary1 GAAP revenue from continuing operations of $1,992.7 million, up 17.2% compared to the prior year period1 Adjusted revenue from continuing operations of $1,983.7 million, up 16.3% compared to the prior year period, and up 15.4% on an adjusted constant currency basis2 GAAP diluted EPS from continuing operations of $1.31, compared to $1.21 in the prior year period Adjusted diluted EPS from contin
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 26, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on February 26, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conferen
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 15, 2025, to shareholders of record at the close of business on November 14, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiol
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the third quarter ended September 28, 2025. Third quarter financial summary GAAP revenue of $913.0, up 19.4% compared to the prior year periodAdjusted revenue of $892.9 million, up 16.8% compared to the prior year period, and up 15.3% on an adjusted constant currency basis1GAAP diluted EPS from continuing operations of $(9.24), compared to $2.36 in the prior year periodAdjusted diluted EPS from continuing operations of $3.67, compared to $3.49 in the prior year period 2025 guidance summary Narrowing GAAP revenue growth guidance range to 9.10% to 9.60% Lo
WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 6, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609